Inventory and characterize — identify each active pharmaceutical ingredient (API), quantity, expiry status, and whether it triggers a hazardous-waste characteristic (e.g. many cytotoxic/chemotherapy agents are listed hazardous wastes).
Segregate at source — separate hazardous pharmaceutical waste from non-hazardous, and controlled substances from non-controlled, each following its own regulatory stream.
Minimize generation — improve inventory control and first-expire-first-out stock rotation; use manufacturer take-back/reverse-distribution programs for near-expiry or recalled stock before it becomes waste.
Store safely and label pending disposal — in appropriately labelled, segregated, secure containers.
Select an approved treatment/disposal route (below) matched to the waste's hazard classification.
Document and report — manifest hazardous shipments, keep chain-of-custody records, and report per applicable regulations (CEPA/provincial hazardous waste regulation).
Train staff on segregation and handling procedures to prevent cross-contamination or improper disposal (e.g. down the drain).
Treatment options:
High-temperature incineration — the most common route for hazardous pharmaceutical waste; destroys the API and, with proper air-pollution controls, safely manages combustion by-products.
Chemical deactivation — for select waste classes (e.g. certain oxidizers/reactive compounds) that can be chemically neutralized before disposal.
Secure hazardous landfill — for solid residuals not suited to incineration, after confirming no free liquids and meeting landfill acceptance criteria.
Reverse distribution/return to manufacturer — for unexpired, recalled or overstock product, avoiding disposal altogether.
Public take-back programs — for consumer-generated pharmaceutical waste, explicitly to keep APIs out of the sanitary sewer, since conventional municipal treatment does not remove most pharmaceuticals and they are ecotoxic (e.g. endocrine-disrupting) even at trace concentrations.
